Observation on clinical efficacy of recombinant human B-type natriuretic peptide in treating dilated cardiomyopathy complicating heart failure
10.3969/j.issn.1671-8348.2014.36.009
- VernacularTitle:重组人 B 型利钠肽治疗扩张型心肌病心力衰竭患者临床疗效观察
- Author:
Xinhua GUO
;
Yongzhong YANG
;
Jianxiu LI
;
Shujie CHEN
;
Lei ZHANG
;
Wei LIU
- Publication Type:Journal Article
- Keywords:
rhBNP;
dilated cardiomyopathy;
NT-proBNP;
heart failure
- From:
Chongqing Medicine
2014;(36):4875-4877,4880
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the short term clinical efficacy of recombinant human B‐type natriuretic peptide(rhBNP) in the treatment of dilated cardiomyopathy complicating heart failure .Methods 121 patients with dilated cardiomyopathy complicating heart failure were selected ,the cardiac function grade Ⅲ - Ⅳ ,and randomly divided into the conventional treatment group(control group ,n= 61) and the rhBNP treatment group(rhBNP group ,n = 60) .The disease history was recorded and clinical symptoms , heart color echocardiography ,cardiac function ,renal function and plasma NT‐proBNP levels were observed before and after treat‐ment .Results The NT‐proBNP level after 72 h treament in the rhBNP group was significantly lower than that in the control group (P< 0 .01) ;LVEDd after 1 week treatment in the rhBNP group was significantly lower than that in the control group ( P =0 .033) ;LVEF was increased in the both groups ,but the increase in the rhBNP group was more significant compared with the con‐trol group (P< 0 .01) .The total effective rate was 91 .6% in the rhBNP group and 72 .1% in the control group with statistical dif‐fernece between the two groups(P= 0 .005) ;the average hospital stay time in the rhBNP group was significantly shorter than that in the control group(P= 0 .041) .The proportion of the major adverse cardiovascular events(MACE) occurrence had no statistical difference between the two groups(P= 0 .492) .Conclusion rhBNP is safe and effective in treating the acute decompensation of di‐lated cardiomyopathy .
